The oldest rule in investing is simple – buy low and sell high. The challenge, of course, is figuring out which beaten-down stocks are genuinely broken and which ones are simply going through a rough patch.

Meet Samuel – Your Personal Investing Prophet

• Start a conversation with TipRanks' trusted, data-backed investment intelligence
• Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

That's where a few reliable signals can help separate potential bargains from value traps. Two of the most closely watched are insider buying and analyst sentiment.

Corporate insiders – executives, directors, and other company leaders – often have a deeper understanding of their business than outside investors. When they start purchasing shares of their own company, especially after a steep decline, it can signal confidence that the market has become too pessimistic.

Analysts can provide another layer of insight. When Wall Street researchers continue backing a stock with Buy ratings despite recent weakness, it suggests they still see a path toward recovery.

Using TipRanks' Insiders' Hot Stocks tool, which tracks meaningful insider buying activity, we pinpointed two stocks that fit this setup – heavily discounted share prices, insider buying, and Strong Buy consensus ratings. Let's take a closer look.

Zenas BioPharma (ZBIO)

First up is a late-clinical-stage medical research company, Zenas BioPharma. This firm is operating at the leading edge of the medical field and boasts a strong pipeline of drug candidates, with applications in the field of autoimmune diseases. This class of diseases offers rich potential for a biopharma researcher – autoimmune conditions are frequently highly resistant to treatment, and so successfully bringing a drug candidate to the approval phases and commercialization is a real prize.

To that end, Zenas has two leading candidates, obexelimab and orelabrutinib, advancing through mid- and late-stage clinical trials. The first of these, obexelimab, is a bifunctional monoclonal antibody that binds the CD19 and FcγRIIb proteins found on the surface of B cells and thereby inhibits those cells' activity in autoimmune conditions – and it does not cause an overall depletion of B cells in the body. That mode of action is designed to address the role of B cells in autoimmune disease without causing immune system compromises. Obexelimab is designed for dosing through self-administered subcutaneous injections.

Currently, Zenas is advancing obexelimab in multiple autoimmune indications, including Immunoglobulin G4-related Disease (IgG4-RD), Relapsing Multiple Sclerosis (RMS), and Systemic Lupus Erythematosus (SLE). On the first of these tracks, the company expects to submit the Biologics License Application (BLA) to the FDA during the current 2Q26 and plans a Marketing Authorization Application to the EMA during the second half of this year. These applications are bolstered by positive topline results from the Phase 3 INDIGO registrational trial in IgG4-RD announced earlier this year. Investors will also be watching closely for additional obexelimab data presentations at the upcoming EULAR 2026 Congress on June 4. On the SLE track, topline results from a Phase 2 study are expected for release in 4Q26.

We should note that, in January of this year, the company released positive Phase 3 data for obexelimab in IgG4-Related Disease (IgG4-RD). While the study met its primary endpoints, some investors appeared underwhelmed after comparing the results to competing therapies. In addition, the company operates at a net loss and, in March of this year, offered both stock and convertible notes to raise capital – that combination raised worries about share price dilution. Overall, ZBIO is down by 46% so far this year.

The second leading candidate, orelabrutinib, is a BTK inhibitor under investigation in the treatment of MS. There are two Phase 3 trials ongoing for this indication, testing the drug against primary progressive multiple sclerosis (PPMS) and against non-active secondary progressive multiple sclerosis (naSPMS).

The final clinical program of note concerns ZB021. This drug is currently in a Phase 1 trial, testing the safety, tolerability, and pharmacokinetic profile of single ascending doses (SAD) and multiple ascending doses (MAD) in healthy volunteers; data is expected by the end of this year. Zenas has plans to start additional trials in psoriasis patients in North America, with results likely to be released next year.

Turning to the insider activity, the timing of the latest purchase stands out given the sharp decline in the stock. The company's CEO, Lonnie Moulder, bought 60,000 shares just this week, spending roughly $1 million to add to his position.

That vote of confidence comes as Wedbush analyst David Nierengarten argues investors may be overlooking the breadth of Zenas' pipeline and the string of potential catalysts expected over the coming quarters.

"ZBIO is progressing toward a diversified pipeline with 2-3 major development candidates and data events roughly every 3-6 months. We see near-term movement with clinical and regulatory developments for obexelimab and ZB021, while orelabrutinib (BTKi) and ZB014 (CD19 mAb, HLE) offer long-term growth potential. ZBIO remains on our Best Ideas List and considering a market cap half that of our valuation in IgG4-RD alone, we see a buying opportunity on current weakness," Nierengarten opined.

Along with these comments, Nierengarten rates ZBIO stock as Outperform (i.e., Buy), and his $45 price target implies a one-year upside potential of 130%. (To watch Nierengarten's track record, click here)

Overall, Zenas gets a Strong Buy consensus rating from Wall Street's analysts, based on 6 recent reviews that include 5 Buys and 1 Hold. The stock is priced at $19.56, and its $43.67 average target price points to a 123% gain by this time next year. (See ZBIO stock forecast)